You are here:    Home About the Foundation Blog

ja_mageia

Children's Tumor Foundation

The latest of all topics concerning NF and Schwannomatosis.
Jul 28
2011

Proteus Syndrome ('Elephant Man') Gene Identified

Posted by Kim Hunter-Schaedle in Research , Children's Tumor Foundation

A team of researchers has identified the genetic mutation that causes Proteus syndrome, a rare disorder in which tissue and bone grows massively out of proportion. Only 300 people  worldwide are believed to be affected by this very rare condition.   The report appears in the July 27, 2011, early online edition of the New England Journal of Medicine.

It has long been speculated that the Elephant Man had Proteus Syndrome. It has been speculated too that in addition to Proteus Syndrome he may also have had NF1 gene mutations, but this has never been demonstrated conclusively. It is known that his clinical appearance would match a severe form of Proteus Syndorme.
The new discovery has broad implications for potential drug therapies and will also potentially inform neurofibromatosis research as well as cancer.  The team was led by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.
 
The mutated gene associated with Proteus Syndrome is AKT1, and is an oncogene i.e. it can promote the uncontrolled cell growth associated with cancer and as seen in Proteus Syndrome. Interestingly AKT1 has also been under consideration as a drug target for neurofibromatosis since it is on the same cellular signaling cascade. 


Jul 26
2011

Video: NF in the News in Minneapolis

Posted by Garrett Gleeson in Untagged 


 

Jul 14
2011

Jeffrey Hanson featured in People Magazine

Posted by George Orfanakos in Untagged 

The incredible story of artist Jeffrey Hanson is featured on page 110 of the issue of People currently on newsstands (it's not online, we've contacted People's staff and it will not run while the issue is on newsstands but may run online thereafter -- we'll update if it does).  Jeff lives with NF1 and had his eye sight severely limited due to an optic glioma that was treated with chemotherapy but not before affecting his optic nerve.  However, Jeff did not let the challenges of NF limit his artistic vision.  He is an accomplished painter and has contributed several works to the Foundation's Gala, all the while donating the funds raised through his work to worthy children's charities, including  more than $50,000 to the Children's Tumor Foundation.  We are very grateful to Jeff and the Hanson family for their dedication to supporting NF research and care, and for the shining example they set for overcoming the challenges of NF.

 

Pictured LtoR: Julie Hanson, George Orfanakos, Jeff Hanson, and Harold Hanson

Jul 05
2011

NF Forum Agenda Announced!

Posted by Garrett Gleeson in Untagged 

The Forum is a great place for individuals and families from across the country to come together for an incredible weekend of education, support and fun!  This year we're excited to offer breakout sessions for our popular “NF Moms Rock!” and “NF Dads Rock!” groups.  We’ll have plenty of activities everyone will enjoy.  From our Children’s Camp to our Teen Adventure to the Young Professionals Networking event, there will be something for everyone.   

Financial assistance is available.

Click here to reigister.

Thursday, July 28, 2011

Pre Conference Events
9:00am- 12:00pm         NF Endurance Team Captain Summit
1:30pm-5:00pm            NF Endurance Team Activity
6:00pm-8:00pm            Chapter Council Dinner


Friday, July 29th, 2011

Pre Conference Events
7:30am - 4:30pm           Chapter Council Meeting
9:00am – 4:30pm           Optional Day Activities
Valley Fair Amusement Park, Science Museum, Target Center, Minnesota Zoo,
Water Park of America, Wild Life Refuge, Mall of America

NF2 and Schwannomatosis Health Fair
11:00am- 5:00pm          NF2/ Schwannomatosis Patient Evaluation (Location: Mayo Clinic Rochester)
11:00am-1:00pm           Transportation from Marriott Minneapolis to Rochester (pick up at 11:00am)
                                           Lunch and  Tour of Mayo Clinic Rochester (open to all NF Forum attendees)
1:00pm-4:00pm             Health Fair for Individuals with NF2 or Schwannomatosis
4:00pm-5:00pm             Question and Answer Panel: NF2/Schwannomatosis

NF Forum Opens

5:30pm – 8:00pm      Welcome Reception & Registration:“A Social Time to Connect Reconnect”
6:30pm                        Opening Session

Keynote Address:  “Adversity is a Gift:  Five Reasons People Survive and Thrive”
Mike Max, Sports Reporter for WCCO TV in Minneapolis

Special Recognition:    Three young people with NF who were honored at the 2011 Prudential Spirit of Community Awards: High School National Honoree Jeffrey Hanson and State Honorees: Zachary Odegard, Oregon and Shoshanna Goldin, Pennsylvania.

Saturday, July 30, 2011

7:30am – 11:00am        Exhibits/ Kids and Teen Venture/NF Forum Registration
7:30am – 8:20am          Breakfast
7:30am- 5:00pm            Kids and Teen Adventure
8:30am- 8:40am            Against All Odds
                                          George Orfanakos - President, Children’s Tumor Foundation
8:40am-9:10am            “Entering the Market Place with Open Hands:  Living an Inspired Life”
                                         Sondra E. Solomon, Ph.D. -University of Vermont
9:10am – 9:30am         Speak up! Government Advocacy
                                         Aubrey Rothrock, Partner and Nicole Silver, Associate, Patton Boggs LLP
9:30am-9:45am            BREAK

Concurrent Sessions

9:45am-11:45pm         NF2 WHAT YOU NEED TO KNOW
    Natural History NF2 - Gareth Evans M.D. -  University of Manchester/St. Mary’s Hospital - Click here to see video of Dr. Evans at the NF Conference.
    Natural History Schwannomatosis - Chris L. Moertel M.D. – University of Minnesota
    Radiation vs. surgery in NF2Gareth  Evans M.D.-  University of Manchester/St. Mary’s Hospital
    Updated Results On Hearing Improvement After Bevacizumab- Scott R.Plotkin M.D. Ph.D. - Massachusetts General Hospital - Click here to see video of Dr. Plotkin.
    Complementary MedicineLarry R. Bergstrom .M.D. – Mayo Clinic

9:45am-11:45pm         NF1 WHAT YOU NEED TO KNOW
   
Clinical Trials: An update on NF1 trialsDavid H. Viskochil M.D., Ph.D. - University of Utah - Click here to see video of Dr. Viskochil discuss his history of researching and improving care for those who live with NF.  
    What's an Optic Glioma- Chris L. Moertel  M.D. - University of Minnesota
    Complementary and Alternative Medicine- Larry R. Bergstrom .M.D. – Mayo Clinic
    NF1 and Your Skin: itching, spots and bumpsTBA

11:45am - 12:00pm       BREAK

12:00pm – 12:45pm       Breakout Sessions: Getting The Word Out – Many Voices One Message!                                 
                                                                                 The Ask: Approaching family, friends, and corporations to support CTF
                                                                                 Special Events: How to take your fundraising idea, organize it, plan it and make it become a reality      
                                                                                 Social Media: How to spread the news of NF & CTF through social media

1:00pm –1:45pm            LUNCH and a Special Video: Cris Crossing the Nation with Inspiration

1:45pm- 3:15pm          NF2 WHAT YOU NEED TO KNOW
      Auditory Brainstem Implantation (ABI) for the NF2 Patient– Brian Neff, M.D. - Mayo Clinic
      Hearing Preservation in NF2 – Sam Levine, M.D - University of Minnesota
      Peripheral Nerve Surgery – Robert J. Spinner M.D. - Mayo Clinic
      Pain Management in NF2 & Schwannomatosis - Tim J. Lamer, M.D. - Mayo Clinic

1:45pm-3:15pm           NF1 LIVING AND LEARNING
     The Psychological and Educational Needs and Services of Children Living with NF
      David Salsberg, Psy.D. DABPS - Rusk Institute, NYU Medical Center
      Laura Tagliareni, Ph.D. - Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders
      NYU Langone      Medical Center


3:15pm-3:30pm             BREAK
3:30pm-4:00pm             Chapter Council “Sharing, Learning and Celebrating”

4:00pm-5:30pm           NF1 & NF2: UNITING TO LEARN MORE
                                        Expert panel: Can We Talk? Conversation about tools for good living, managing stress, anxiety and uncertainty in NF
5:30pm                          Wrap Up and Directions for Walking with Nature
7:00pm-9:00pm           Dinner, Partying and Picnicking

Sunday, July 31, 2011

7:45am                         Walk with Nature and Picnic
                                       NF Walk: Departure from Marriott to Minnehaha Park (transportation provided)
8:00am- 8:45am         Breakfast and Registration - Minnehaha Park
9:00am                         Walk Begins/Picnic following walk
                                       (transportation from Minnehaha park to Marriott)

Register Now!

Jun 30
2011

Children’s Tumor Foundation Sets Priorities to Advance Schwannomatosis Research

Posted by Garrett Gleeson in schwannomatosis , Preclinical Drug Testing , pain , genetics , Children's Tumor Foundation

The following was written by CTF Chief Scientific Officer Dr. Kim Hunter-Schaedle:

Earlier this week the Children’s Tumor Foundation hosted a workshop/think tank convening 25 international researchers and clinicians to review recent progress in schwannomatosis research and clinical management, and set priorities to advance future progress. The meeting was planned and chaired by Dr. Scott Plotkin (Harvard/MGH), Dr. Marco Giovannini (House Research Institute) and Dr. Gareth Evans (University of Manchester) and included updates on genetics, cell biology, surgical intervention and the potential of advancing to clinical drug therapies for schwannomatosis, the rarest form of neurofibromatosis affecting an estimated 1:40,000 persons.

In part through CTF funded projects, significant progress has been made since the gene SMARCB1 (also known as INI-1) was in 2007 identified as a causal factor in inherited schwannomatosis.  Researchers have further unraveled the genetics of schwannomatosis, and learned that while SMARCB1 is important in inherited cases of schwannomatosis, this disease onset also involves the NF2 gene; and that in spontaneous (non-inherited) cases, SMARCB1 is not necessarily involved but that there are as yet unidentified genes involved.   The first mouse models of schwannomatosis tumors and pain are now developed and being used to study tumor and pain biology and test drug therapies.  And an international schwannomatosis database is established to collect information on schwannomatosis patients worldwide and facilitate future research projects and clinical trials.

At the workshop a series of priorities for the future was identified. There is a need to identify the additional genes and genetic modifiers that may be involved in interacting with the SMARCB1 or NF2 genes to lead to schwannomatosis. There is a need to develop more refined mouse models that represent schwannomatosis seen in humans as closely as possible, so that these can be used to study biology and tumor growth/pain and to test candidate drug treatments.  The biology and mechanisms of pain - which is such a central and poorly understood element of schwannomatosis - need to be unraveled and understood.  In terms of candidate drug therapies, it is rational to look at those drugs that are showing promise in mouse models of NF2 tumors, and see if they have impact on the tumors in mouse models of schwannomatosis.

Very importantly, now that we have a patient database, there is a need to plan clinical research studies to better understand schwannomatosis, such as understanding how individual patients condition has progressed following surgery, especially multiple surgeries; identifying whether there are blood-based or other biomarkers of schwannomatosis; and developing a pain survey for patients to better define the type and range of pain seen in schwannomatosis.; and looking ahead, prospective studies monitoring patients from time of diagnosis ongoing such as by whole body MRI. It is considered to be premature to consider clinical trials for schwannomatosis as we don’t have sufficient knowledge to do this; but that for patients in states of extreme crisis, there is the potential to begin testing drugs such as bevacizumab (Avastin) that have shown promise in NF2 patients.

Finally the clinical diagnostic guidelines for schwannomatosis were published in 2005 and the group reviewed these and made some recommendations to update these based on new genetics and clinical knowledge.

As a follow up to this workshop CTF will be spearheading the publication of a meeting report summarizing the latest update and recommendations for schwannomatosis. Also – in the next month – CTF will be releasing a Request for Applications to fund further schwannomatosis research.  After this great meeting we look forward to seeing further research progress.

Jun 30
2011

New Video from the 2011 NF Conference

Posted by Garrett Gleeson in schwannomatosis , NF2 , NF1 , NF Conference , neurofibromatosis

Jun 29
2011

Stories of NF: Fred

Posted by Garrett Gleeson in Stories of NF , NF2 , neurofibromatosis

Can you hear the silence?

I can. Always. I’m deafened since I was 17 due to Neurofibromatosis Type 2 and since then live in complete silence. What proved at first an enormous strike in life, I have now found ways to cope with. The first step was acceptance of this fate. Not that I have swept it aside and carry on living but rather I've found ways of lessening the pain which deafness brings. At first, there was the language part. If you want to enjoy your time with somebody else, you need a shared language to achieve this. For me and my family this meant learning sign language and I, over time, taught this to my closest friends, so they can find a way back to my real self. Of course this is a small world, but it’s better than being completely isolated, because no doubt this is what happens after ‘the strike’. What you thought to be friends, move away from you except very few close ones if you’re lucky. You lose the grip of the world you belong to and with it your identity until only your family is left. NF2 is so different in every individual though and many will have different perceptions and experience, but this is how I experienced it after becoming deaf.

So, suddenly without being part of either world; Nor the hearing one, neither the one of the deaf (from birth) community, I seemed and still seem a bit lost when it comes to where I belong. I would say I’m from in-between the two worlds and that sadly is quite a small margin. In public I find myself being avoided, it is almost impossible to meet new people. They all avoid me, but when I take that thought further I realise it’s not me directly, but rather communication with me. So, I keep telling myself it is their loss, I like myself. Of course though, it is mine, too. Due to the failing smalltalk (who thought this would be important?) I feel shut out from personalities, from information, from other human-beings in general. I always have to work hard and get to know many people, because there might be just be someone who will not follow this general pattern. After all I have interesting things to tell and in some way or another I can slip something maybe interesting about myself (not my disease etc.) in to provoke further interest. So, actually it is an on-going fight about re-integrating myself back into society or maybe it is just a straw of my past and true identity which I do not want let go.

Another basic of life, along with health, communication and a working social environment is that of the family. I do not know what I would do without them, just like anybody who hears says the same for his ears. Although they support me in any way possible, despite their helplessness, I know I would move on without them, because I must, because I have no other choice than trying making the best of it. Of course we all felt completely lost when we suddenly had to communicate by pen and paper after the first surgery. But after a few years we all began to understand the real meaning of the saying ‘time heals all wounds’. It is really hard to keep your spirits up if the society’s behaviour just pulls them down again. NF2 has really redefined true family love within mine and in some way or another I am even grateful for this fate. It enabled me to meet many nice people, to make new experiences, to learn what life is worth. I had one of the best childhood’s you could wish for and that can never be taken away. I have taken these words as my new motto: ‘Don’t cry because it’s over. Smile because it happened.’

I am a language student at Southampton University, which has, having grown up in Germany, always been my dream (before deafening). I thought to myself ‘why should the deafness stop me?’, so I just continued with it and it works well. Having me as a student means extra work for the tutors etc. and of course for myself, but I’m up for it. There is lots of support available, all you have to do is raise your hand. Generally I enjoy challenges and that’s what keeps me going. I see NF2 not as a disability itself (the feeling of being disadvantaged is created by society) but as a challenge. And I won’t give up before it is resolved. Many people complain about not knowing to do with their lives, having no essence. For me NF2 is a sense of life. It is certainly not boring and made me what I am today. And when I look around me, without being arrogant I believe I am a better person than some, who are just not aware of the value of life, who just lead the same boring life as always and being somewhat superficial. In Shantaram, the best book I have ever read, a sentence goes ‘If you can’t do anything about something, you have to accept that things could be worse and that you are completely helpless in the face of it’ but Voltaire said ‘the longer we dwell on misfortunes, the greater is their power to harm us.'

So yeah, guess I gotta keep moving.

Jun 27
2011

NFE's RAAM Team Completes the Journey

Posted by George Orfanakos in Untagged 

Official time: 8 days 5 hours and 1 minute

That’s how long it took our NF Endurance team members to complete the Race Across America (RAAM).  From the first tire track in Oceanside, California to the journey’s completion (fittingly) in Annapolis, Maryland, RAAM is the story of commitment to a cause greater than its participants.  Each rider, and each crew member, battled the elements and the obstacles to raise awareness about NF and raise funds to advance treatments for the disorder. 

It’s a remarkable feat, one that speaks to the incredible commitment of our four riders, Steve, Connie, CB, and Rodney, and their supporting crew – we are grateful and fortunate to have such wonderful people champion our cause. 

The RAAM event, with its ups and downs, high points and lows, is a strong metaphor for the challenges that families battling NF endure.  The uncertainties of the journey can be troubling but with the strength of the crew/family’s support, coupled with the backing of the Children’s Tumor Foundation, we can and will find treatments and a cure for NF together.  Together we’ll reach our goal, and it is the efforts of our RAAM team, and the many of you throughout the country who every day work to support our cause, that we will end NF through research. 

Congrats to our RAAM team, I hope they’re enjoying a well-deserved rest after this truly remarkable accomplishment.

Ed note: For more on the RAAM team please visit their site at http://ridenforareason.org/.

Jun 26
2011

From LA: CTF Convenes Schwannomatosis Experts; Acoustic Neuroma Meeting Follows

Posted by Kim Hunter-Schaedle in schwannomatosis , Research , Preclinical Drug Testing , pain , genetics , Children's Tumor Foundation

On June 27th-28th the Children's Tumor Foundation is convening a Schwannomatosis Workshop (think tank) in Los Angeles. International expert researchers and clinicians will review the most recent findings in schwannomatosis research and clinical care, share progress and chart the future path to improving care and finding effective treatments for schwannomatosis.  I look forward to reporting the outcome of  the next 2 days of meetings. Below is a preview to set the stage.

I'll be staying in LA for the remainder of the week to attend the Acoustic Neuroma 2011 Meeting which includes a lot of NF2-relevant presentations, and will be reporting on that later in the week too. 
Schwannomatosis is the most rare form of neurofibromatosis affecting an estimated 1:40,000 persons. It causes the growth of multiple peripheral nerve tunors called schwannomas, and in addition it causes chronic, severe and unmanageable pain. There are no treatments for this. For a long time schwannomatosis was not well understood and in fact the first guidelines for its clinical diagnosis were not published until 2005.  A breakthrough came in 2007 with the publication of the first candidate schwannomatosis gene, INI-1/SmarcB1/Snf5. This gene has emerged to be a key player in schwannomatosis but interestingly there may also be involvement of the NF2 gene in the onset and progression of schwannomatosis. Schwannomatosis research faces added challenges as there are so few patients, so to accelerate progress CTF has brought this community of researchers and clinicians together since 2007 for a series of think tanks and they have shared and collaborated extensively with each other. CTF has been a major force in advancing schwannomatosis research in the past 4 years since the candidate gene was identified. In addition to hosting the think tanks, CTF has invested more than $700,000 in schwannomatosis research in this period. Projects we have funded include the creation of a schwannomatosis patient database now up and running;  the creation of the first 2 mouse models of schwannomatosis, both of which are now  being utilized for preclinical drug testing to reduce tumor growth and pain; and further genetics studies. Look for updates from the schwannomatosis think tank in the next day or so!

Jun 23
2011

Guest Blog: Search for NF1 Genetic Modifiers Seeks Patients and Researchers to Participate

Posted by Kim Hunter-Schaedle in Research , NF1 , NF Conference , neurofibromas , genetics

Today we feature a Guest Blog featuring a report from the 2011 NF Conference from Dr. Fawn Leigh, a pediatric neurologist at the Massachusetts General and Harvard Medical School. Dr. Leigh presented the following project at the Conference, and is looking for further research collaborators, as well as any persons with NF1 who would be willing to participate and donate tissue, whether or not they are currently under care of an NF clinic.

At the 2011 NF Conference in Jackson Hole I gave a talk highlighting my findings from a pilot study to identify modifier genes that may inform the identification of potential drug targets and treatments in NF1. The study focused on a search for modifier genes of cutaneous (dermal) neurofibroma tumor burden in NF1. This was done through a genome-wide association study (GWAS).  300 NF1 subjects identified as having either the largest or least 15% of cutaneous tumor burden were genotyped using the Affymetrix GeneChip 6.0 platform. This provided 909, 622 single nucleotide polymorphism (SNP) markers and >946,000 probes for copy number variants (CNV).  The analysis revealed potential hits (P values of 10-4 to 10-7) with multiple SNPs at each of several regions of the genome. Each of these segments constitutes a candidate region that merits genotyping in an additional cohort of extreme subjects to either confirm or refute its modifier status, which is ongoing.  The CNV analysis is in progress. The current GWAS study is a collaboration of six centers across the world.  Five new centers recently joined this project. 

For researcher or patients seeking additional information about participating in this study, please contact:  Stephen Ranney (Clinical Research Coordinator)

Email: administrator@cnfad.org               Office: 617-724-2365

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Upcoming Events

Sat Feb 11, 2012 @ 2:00pm -
Wisconsin: Tea for NF
Fri Feb 17, 2012 @ 4:00am - 10:00pm
Michigan: Red Wings 50/50 Raffle
Sat Feb 18, 2012 @ 8:00pm -
Arizona: CTF Benefit Concert - (X Factor) TORA WOLOSHIN
Sat Feb 25, 2012 @10:00am - 02:00pm
Arizona: Spring For A Cure
Sat Mar 03, 2012 @ 7:00pm -
NJ: Coffeehouse for a Cure
Sun Mar 04, 2012 @ 3:00pm -
NY: CTF Night with the NY Islanders

Sign-Up for BLOG Notifications
Enter your email address:


Delivered by FeedBurner

 

Racing 4 Research Logo
Fuel The Cure


NF Walk
Every step makes a difference


NF Endurance Logo


NF Camp

 
List of Events


whatsNick


adLeft_214

 


Facebook

Twitter